
Starting with the 1980s, the inhibition of cyclic nucleotide phosphodiesterase type 5 (PDE5) as a therapeutic target has received considerable attention, particularly for the treatment of male erectile dysfunction and cardiovascular diseases, e.g., angina, hypertension, and congestive heart failure. Around the mid-1980s scientists working at the Pfizer European Research Centre were interested in potential new […]